News Related to Synthetic Oral Macrocyclic Peptide Drugs

Related coverage linked through entity extraction aliases.

Novartis Signs Up to $1.8B Licensing Deal with UNP for Cardiovascular Peptide Therapeutics

Feb 18, 2026

Novartis has signed a research partnership and licensing agreement with Unnatural Products valued at up to $1.8 billion to develop macrocyclic peptide therapeutics targeting cardiovascular diseases using AI-driven drug discovery.

Novartis, Unnatural Products Sign $1.8B Cardiovascular Macrocyclic Peptide Deal

Feb 18, 2026

Unnatural Products entered a research collaboration and licensing agreement with Novartis worth up to $1.8 billion to develop orally-delivered macrocyclic peptide therapeutics for an undisclosed cardiovascular program.